| Arcalyst — gout-flare prevention | 1 | Use maximum tolerated NSAID and colchicine, with concurrent urate-lowering therapy. | Inadequate response, intolerance, or contraindication to both NSAID and colchicine; at least two gout flares in the prior 12 months also required for new starts. |
| Atovaquone — PCP treatment or primary toxoplasmosis prophylaxis | 1 | Sulfamethoxazole/trimethoprim (SMX-TMP). | Inadequate response, intolerance, or contraindication; prophylaxis also requires immunocompromised status. |
| Atovaquone — babesiosis | 1 | Azithromycin concurrently. | Concurrent therapy is required; no failure exception stated. |
| Bosulif / bosutinib — CML | 1 | Imatinib, dasatinib, or nilotinib. | Resistance or intolerance; resistant cases must also be negative for specified mutations. |
| Brivaracetam — focal-onset seizures | 1 | A generic anticonvulsant; Xcopri when the patient is 18 or older. | Inadequate response, intolerance, or contraindication to the applicable therapy. |
| Bysanti — schizophrenia or bipolar I mania/mixed episodes | 1 | One listed generic antipsychotic followed by one listed brand antipsychotic. | Inadequate response, intolerance, or contraindication to each step. |
| Cabometyx — GIST | 1 | At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib. | Disease progression after the prior therapies. |
| Antipsychotics — schizophrenia | 1 → 2 | One listed generic antipsychotic, followed by one listed brand antipsychotic. | Inadequate response, intolerance, or contraindication at each step. |
| Antipsychotics — acute bipolar I mania or mixed episode | 1 → 2 | One listed generic antipsychotic, followed by Lybalvi or Vraylar. | Inadequate response, intolerance, or contraindication at each step. |
| Calcipotriene or Enstilar — plaque psoriasis | 1 | At least one topical corticosteroid. | Inadequate response or intolerance, unless a contraindication prevents a corticosteroid trial. |
| Cresemba — invasive aspergillosis or fluconazole-refractory HIV-associated esophageal candidiasis | 1 | Voriconazole before Cresemba. | Inadequate response, intolerance, or contraindication to voriconazole. |
| Drizalma Sprinkle — major depressive disorder | 1 | Two antidepressant agents or classes selected from SNRIs, SSRIs, mirtazapine, or bupropion. | Inadequate response, intolerance, or contraindication to two alternatives. |
| Ensacove — ALK-positive NSCLC | 1 | Prior ALK-inhibitor therapy when previously treated. | No prior ALK inhibitor is acceptable; otherwise intolerance or progression with crizotinib is required. |
| Droxidopa / nOH | 1 | Qualifying nOH diagnosis and objective orthostatic blood-pressure decrease before initial therapy. | Systolic decrease of at least 20 mmHg or diastolic decrease of at least 10 mmHg within 3 minutes; continuation requires sustained symptom reduction. |
| Ergotamine — migraine | 1 | At least one triptan 5-HT1 agonist. | Inadequate response, intolerance, or contraindication. |
| Eprontia — focal-onset seizures | 1 | A generic anticonvulsant; Xcopri when the patient is 18 or older. | Inadequate response, intolerance, or contraindication to the applicable therapy. |
| Fanapt — schizophrenia or bipolar I mania/mixed episodes | 1 → 2 | One listed generic antipsychotic followed by one listed brand antipsychotic. | Inadequate response, intolerance, or contraindication to each step. |
| EMSAM, Exxua, or Fetzima — major depressive disorder | 1 | Two agents or classes selected from SNRIs, SSRIs, mirtazapine, or bupropion. | Failure, intolerance, or contraindication; EMSAM also permits inability to swallow oral formulations. |
| Gilotrif — EGFR-positive NSCLC | 1 | Erlotinib, gefitinib, or osimertinib. | Intolerable adverse event or contraindication; metastatic squamous NSCLC instead requires prior platinum-based chemotherapy. |
| Tricyclic antidepressants — depression | 1 | Two alternatives from SSRIs, SNRIs, bupropion, mirtazapine, or trazodone. | Inadequate response or intolerance to two alternatives. |
| Benztropine — extrapyramidal symptoms | 1 | Amantadine. | Inadequate response or intolerance after a trial, or contraindication without a prior trial. |
| Benztropine — Parkinson’s disease | 1 | Two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole. | Inadequate response or intolerance to two alternatives. |
| High-risk medications — anxiety | 1 | Two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release. | Inadequate response or intolerance to two alternatives; acute anxiety is an exception. |
| Zolpidem — insomnia | 1 | Doxepin 3 mg or 6 mg, or ramelteon. | Trial with inadequate response or intolerance, or contraindication to both alternatives. |
| Promethazine — rhinitis | 1 | Two of levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal. | Inadequate response or intolerance to both alternatives. |
| Hydroxyzine — alcohol withdrawal syndrome | 1 | Clorazepate or lorazepam. | Inadequate response or intolerance after a trial, or contraindication without a prior trial. |
| Zolpidem — depression | 1 | Two SSRIs, SNRIs, bupropion, mirtazapine, or trazodone alternatives. | Inadequate response or intolerance to two alternatives. |
| Iclusig — chronic-phase CML | 1 | At least two prior kinase inhibitors, including imatinib, dasatinib, or nilotinib when applicable. | Resistance or intolerance; exceptions include accelerated/blast phase, T315I mutation, or specified BCR-ABL1 resistance pathway. |
| Iclusig — GIST | 1 | At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib. | Disease progression after prior therapy. |
| Imatinib or Imkeldi — c-KIT-mutated cutaneous melanoma | 1 | Prior BRAF-targeted therapy. | Progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| Imatinib — selected lymphoma indications | 1 | Subsequent, second-line, or later therapy, or prior chemoimmunotherapy as applicable. | Relapsed/refractory disease or the specified prior-treatment setting. |
| Inluriyo — recurrent breast cancer | 1 | At least one line of endocrine therapy. | Disease progression following endocrine therapy. |
| Extended-release hydrocodone or morphine | 1 | Alternative pain therapy, including immediate-release opioids; continuation requires at least 30 days of extended-release opioid therapy or 1 week of immediate-release opioid therapy. | Alternatives inadequate; qualifying opioid exposure and safe dosing must be documented. |
| Jakafi — specified polycythemia vera or essential thrombocythemia indications | 1 | Hydroxyurea, Besremi, interferon therapy, or anagrelide, as applicable. | Inadequate response, intolerance, resistance, or loss of response as specified. |
| Leqembi Iqlik — maintenance therapy | 1 | At least 18 months of prior intravenous lecanemab-irmb infusions. | Minimum prior-treatment duration is required. |
| Megestrol acetate — cancer-related cachexia | 1 | Megestrol 40 mg/mL oral suspension. | Inadequate response or intolerance. |
| Lorbrena — ROS1-positive NSCLC | 1 | Crizotinib, entrectinib, repotrectinib, or taletrectinib. | Disease progression on the prior ROS1-directed therapy. |
| Mekinist or Mektovi — BRAF-mutated indications | 1 | Required BRAF-directed combination: dabrafenib or encorafenib, depending on indication. | Combination therapy is required; no general failure exception stated. |
| Mavyret — hepatitis C | 1 | Treatment conditions and regimen selection must follow current AASLD-IDSA guidance. | Requirements vary by genotype, prior treatment, cirrhosis, resistance, HIV, and transplant status. |
| Lynparza — breast cancer pathway 1 | 1 | At least two prior therapies. | Required for recurrent, advanced, metastatic, or preoperative-treatment-unresponsive disease; an early-stage HER2-positive pathway follows adjuvant trastuzumab-based therapy instead. |
| Opipza — indication-specific psychiatric use | 1 → 2 | Specified generic and, where applicable, brand antipsychotic trials. | Failure, intolerance, or contraindication; inability to swallow oral formulations is an alternative pathway. |
| Pazopanib — GIST | 1 | At least two FDA-approved treatments, such as imatinib, sunitinib, regorafenib, or ripretinib. | Disease progression; step is not required when GIST is SDH-deficient. |
| Perampanel — partial-onset seizures | 1 → 2 | A generic anticonvulsant, followed by Xcopri for adults. | Inadequate response, intolerance, or contraindication to each applicable therapy. |
| Pimecrolimus — atopic dermatitis | 1 | At least one first-line topical therapy, such as a medium- or higher-potency topical corticosteroid, when sensitive-area criteria are not met. | Inadequate response, intolerance, or contraindication. |
| Perampanel — seizure indications | 1 → 2 | Generic anticonvulsant; Xcopri additionally for adults with partial-onset seizures. | Inadequate response, intolerance, or contraindication to the required therapy. |
| Pimecrolimus — first-line therapy pathway | 1 | At least one first-line therapy, such as a medium- or higher-potency topical corticosteroid. | Required when qualifying sensitive-area disease is not established; failure, intolerance, or contraindication applies. |
| Quetiapine extended-release | 1 | Specified generic antipsychotic alternatives according to indication. | Inadequate response, intolerance, or contraindication. |
| Remicade or Renflexis — new starts | 1 | Methotrexate, NSAID, immunosuppressive therapy, phototherapy, or specified conventional agents, as applicable to the indication. | Inadequate response, intolerance, or contraindication; severity-based psoriasis pathways may apply. |
| Qinlock — GIST | 1 → 2 → 3 | At least three kinase inhibitors including imatinib, or imatinib followed by second-line sunitinib. | Intolerance to second-line sunitinib is an alternative to completing three inhibitors. |
| Rubraca — metastatic castration-resistant prostate cancer | 1 | Androgen receptor-directed therapy, with concurrent GnRH analog therapy or bilateral orchiectomy. | Prior androgen receptor-directed therapy is required. |
| Scemblix — chronic-phase CML | 1 | Imatinib, dasatinib, or nilotinib, unless the T315I pathway applies. | Resistance or intolerance, or qualifying prior treatment for previously treated CML. |
| Sorafenib — GIST | 1 | At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib. | Disease progression after prior therapy. |
| Stivarga — colorectal cancer | 1 | Prior treatment and Lonsurf (trifluridine/tipiracil) when applicable. | Inadequate response, intolerance, or contraindication to Lonsurf. |
| Tadalafil — BPH | 1 → 2 | Both an alpha blocker and a 5-alpha reductase inhibitor. | Inadequate response, intolerance, or contraindication to both. |
| Tasigna / nilotinib — GIST | 1 | At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib. | Disease progression after prior therapy. |
| Temazepam — short-term insomnia | 1 | Doxepin 3 mg or 6 mg, or ramelteon. | Inadequate response, intolerance, or contraindication; applies to patients 65 years or older. |
| Tofacitinib — applicable inflammatory conditions | 1 | At least one TNF inhibitor. | Inadequate response, intolerance, or contraindication for new starts; continuation requires beneficial response. |
| Trintellix — major depressive disorder | 1 | At least one generic SNRI, SSRI, mirtazapine, or bupropion. | Inadequate response, intolerance, or contraindication. |
| Truxima — rheumatoid arthritis | 1 | Methotrexate or a prior biologic or targeted synthetic DMARD. | Inadequate response, intolerance, or contraindication to methotrexate, or inadequate response/intolerance to prior DMARD therapy. |
| Ubrelvy — acute migraine | 1 | At least one triptan 5-HT1 receptor agonist. | Inadequate response, intolerance, or contraindication. |
| Uceris — active mild-to-moderate ulcerative colitis | 1 | At least one 5-ASA therapy. | Inadequate response, intolerance, or contraindication. |
| Ubrelvy — acute migraine | 1 | At least one triptan 5-HT1 receptor agonist. | Inadequate response, intolerance, or contraindication. |
| Uceris — active mild-to-moderate ulcerative colitis | 1 | At least one 5-ASA therapy. | Inadequate response, intolerance, or contraindication. |
| Versacloz — treatment-resistant schizophrenia | 1 → 2 | One listed generic antipsychotic followed by one listed brand antipsychotic. | Inadequate response, intolerance, or contraindication to each step. |
| Xyrem — adult narcolepsy with excessive daytime sleepiness | 1 | A CNS wakefulness-promoting drug, such as armodafinil or modafinil. | Inadequate response, intolerance, or contraindication; not required for patients younger than 18 or for cataplexy-only requests. |
| Wyost or Xtrenbo — hypercalcemia of malignancy | 1 | Intravenous bisphosphonate therapy. | Disease must be refractory, or there must be a clinical reason to avoid IV bisphosphonate therapy. |
| Zonisade — partial-onset seizures | 1 → 2 | A generic anticonvulsant and, for patients 18 or older, Xcopri. | Inadequate response, intolerance, or contraindication; difficulty swallowing solid oral dosage forms is an alternative pathway. |